Already a member? Sign in
Category: Others
See also: Clinical Trial
NCT00256750 is belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial. Other study IDs include: IM103-008, BENEFIT.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Transplant rejection prevention | 1 | 1 |
|
See 1 patient currently using Kidney Transplant Phase 3 Belatacept BENEFIT
Mouse over the table for more information
| 750 mg monthly | ||
|---|---|---|
1
|
||
Adherence
Taking treatment as prescribed
Adherence of Kidney Transplant Phase 3 Belatacept BENEFIT
Always |
1 | 100% |
|
|---|---|---|---|
Usually |
0 | 0% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Kidney Transplant Phase 3 Belatacept BENEFIT
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
0 | 0% |
|
A little |
0 | 0% |
|
Not at all |
1 | 100% |
|
Cost
Paid out of pocket
Cost of Kidney Transplant Phase 3 Belatacept BENEFIT
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
0 | 0% |
|
< $25 |
1 | 100% |
|
Report created on May 23, 2012.